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Foot-and-mouth disease virus (FMDV) is one of the most contagious agents of animals. Recent disease outbreaks in FMD-free countries
have prompted the development of new control strategies that could improve the levels of protection against this virus. We have delivered a
plasmid expressing a short hairpin RNA (shRNA) directed against a highly conserved sequence in the 2B nonstructural protein coding region
of FMDV RNA to porcine cells. After virus infection, these cells showed a significant reduction in the synthesis of viral RNA and proteins,
as well as a decrease in virus yield when compared to control cells. The antiviral effect was sequence specific and not attributable to induction
of the interferon pathway. Since FMDV is an antigenically variable virus, we examined the effectiveness of this strategy against multiple
serotypes and found that expressed 2B shRNA resulted in efficient silencing of at least 4 FMDV serotypes. Thus, RNA interference may be a
potential alternative control strategy to limit the spread of this highly contagious virus in livestock.
Published by Elsevier Inc.
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Foot-and-mouth disease (FMD) is an extremely conta-
gious disease that affects cattle, swine and other livestock
worldwide. The disease has been known for five centuries
(Fracastorious, 1546) and its causative agent, foot-and-
mouth disease virus (FMDV), was the first virus ascribed to
an animal illness (Loeffler and Frosch, 1897). Studies over
the years have led to the implementation of vaccination
programs against FMDV that resulted, after 1989, in the
successful eradication of FMD from Western Europe.
However, recent outbreaks in Taiwan (1997) and the United0042-6822/$ - see front matter. Published by Elsevier Inc.
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Hat, Alberta, Canada T1A 8K6.Kingdom (2001), with devastating economic and social
impact, have raised the awareness about the limitations of
current methods to control this disease.
FMDV contains a positive-sense, single-stranded RNA
genome, and is the prototype member of the Aphthovirus
genus of the Picornaviridae family. The virus is antigeni-
cally variable and consists of 7 serotypes and multiple
subtypes. FMDV replicates very rapidly within the infected
animal and spreads among in-contact susceptible animals by
aerosol or direct contact. Disease signs can appear as early
as 2 days post-exposure to the virus.
The current vaccine is an inactivated whole virus
preparation administered with an adjuvant (Doel, 2003).
Recently, a replication-defective human adenovirus type 5
vector (Ad5) containing the capsid coding region of
serotype A24 Cruzeiro and the FMDV 3C proteinase coding
region has been developed and can protect both swine and
cattle from homologous challenge (Moraes et al., 2002;05) 222–231
Fig. 1. Schematic description of the approach followed to identify targets
for RNAi in FMDV. (A) Map of FMDV genome; viral proteins are
indicated in the boxed area. Horizontal bars indicate approximate sequence
locations targeted by RNAi. (B) DNA sequence of oligonucleotides
designed to anneal and clone into the U6 promoter-containing expression
vector. Also shown is the expected hairpin formed after transcription by
RNA polymerase III. (C) Representation of plasmids cotransfected to assess
silencing of FMDV sequences in vitro.
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specific, an effective control strategy requires constant
epidemiological surveillance to identify relevant serotypes
that must be included in an antigen bank. In addition,
neither of the above vaccines can induce complete
protection prior to 7 days post-inoculation. Early protection
is required in the event of an FMD outbreak in a disease-free
country to prevent virus amplification and disease spread.
Chinsangaram et al. (2003) and Moraes et al. (2003) have
shown that inoculation of an Ad5 vector encoding the gene
for the antiviral protein, porcine interferon (IFN) alpha or a
combination of Ad5s expressing IFN alpha and FMDV
capsid and 3C proteinase coding regions completely
protected swine when challenged from 1 to 5 days later.
However, administration of the antiviral alone conferred
only limited protection in cattle (Wu et al., 2003). Thus, the
development of new rapid-acting antiviral strategies effec-
tive against all serotypes and all FMDV-susceptible species
is imperative.
RNA interference (RNAi) is a natural process by which
double-stranded RNA directs sequence specific post-tran-
scriptional gene silencing (Fire, 1999; Hammond et al.,
2001; Sharp, 2001). Specific inhibition of endogenous or
pathogen mRNA by RNAi can be triggered by the
introduction of 21–23 nucleotide (nt) duplexes of RNA
(siRNAs) or by transcription of DNA precursors into short
hairpin RNAs (shRNAs) homologous to target sequences
(Brummelkamp et al., 2002; Elbashir et al., 2001;
Paddison et al., 2002). Over the past years, several
laboratories have used this technology to attenuate viral
infection in cell culture (Coburn and Cullen, 2002; Ge et
al., 2003; Gitlin et al., 2002, Jacque et al., 2002; Phipps et
al., 2004; Seo et al., 2003). Furthermore, studies in
animals injected with plasmids encoding shRNAs directed
against hepatitis B virus have raised expectations about the
use of RNAi as an antiviral strategy (McCaffrey et al.,
2003).
Recently, Chen et al. (2004) and Kahana et al. (2004)
have demonstrated, in cell culture, that siRNAs can be
effective against the FMDV strain to which they were
designed. Furthermore, Chen et al. (2004) have extended
this approach to a suckling mouse model demonstrating
decreased susceptibility to viral infection. However, to be
an effective antiviral strategy against FMDV, this
approach must address the antigenic variability of the
virus.
Here, we demonstrate that an siRNA directed against a
conserved sequence within the coding region of viral
nonstructural (NS) protein 2B of FMDV is capable of
inhibiting virus replication in infected porcine cells (IBRS-
2) by approximately 97–98%. The expression of viral
RNA and proteins was significantly reduced. Stimulation
of the IFN pathway was ruled out as the source for
inhibition. Importantly this 2B-specific siRNA reduced
virus yield in cells infected with 4 different FMDV
serotypes.Results
shRNAs trigger the silencing of conserved FMDV genome
sequences
To determine if RNAi could silence specific FMDV
sequences, we constructed several plasmids expressing
candidate shRNAs and tested them against target sequences
cloned into a firefly luciferase reporter plasmid. Based on
the alignment of multiple sequences corresponding to
different FMDV serotypes, seven highly conserved regions
along the viral genome were selected (Fig. 1A). Three of
them mapped to the 5V untranslated region (5VUTR), that is,
CRE, IRES1 and IRES2, two to the 2B coding region, that
is, 2B1 and 2B2, one to 2C and one to 3D. As a control, a
non-specific shRNA, directed against green fluorescent
protein mRNA (GFP) was used. As reported previously
(Sui et al., 2002) and confirmed in our experiments,
GFPshRNA does not appear to have off-target effects. The
expressed hairpins produce 21 nt siRNAs with 19 bases of
homology to FMDV and 3V overhang U’s (Fig. 1B). The
cloned target sequences each contained about 500–700 base
pairs of the FMDV A12 genome fused to the firefly
luciferase gene (Fig. 1C). HEK-293 cells were transiently
Fig. 3. Inhibition of FMDV replication in swine cells by RNAi. Transfected
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plasmids (shRNA/reporter) and 24 h later luciferase activity
was measured. When we measured the ratio of luciferase
activity for each combination (FMDV specific-shRNA/
GFPshRNA), different levels of silencing were observed
(Fig. 2). One hairpin, 2B1, produced about 90% of specific
silencing. Other hairpins, IRES1, IRES2 and 3D displayed
significant levels of silencing (about 50%) but not as high as
2B1. Some hairpins, CRE, 2B2 and 2C, resulted in no
inhibition or an increase of luciferase activity. The ability of
2B1shRNA to induce specific silencing suggested that
FMDV sequences could be targeted by RNAi.
2B1 shRNA induces potent inhibition of viral replication in
swine cells
To examine whether shRNAs could inhibit viral repli-
cation in cell culture, all plasmids expressing specificFig. 2. Silencing of FMDV sequences by short hairpin RNAs. (A) Target
sequences of FMDV A12-IC assayed in vitro for RNAi. (B) Firefly
luciferase activity determined on HEK-293 cells cotransfected with reporter
plasmid and plasmid expressing shRNA. The activity is expressed as the
ratio between FMDV specific/GFP-control shRNAs. The average of three
independent transfections is shown, error bars indicate the standard
deviation.
IBRS-2 cells (106) were infected with 100 pfu of FMDVA12-IC. After 1 h
adsorption, the cells were washed once with 20 mM MES (pH = 6.0), 150
mM NaCl and once with complete media. Complete media was replaced at
the end of the washes. Virus yield was determined 24 hpi. Error bars
represent the standard deviation from three independent experiments.shRNAs, control GFPshRNA or vector control were
individually transfected in IBRS-2 cells, and 48 h later,
the cells were infected with 100 pfu of FMDV A12-IC
(infectious clone), and incubated overnight. As an additional
control, non-transfected cells were treated identically. As
shown in Fig. 3, the virus yield from cells transfected with
vector control or plasmid expressing GFPshRNA was
similar (100%—approximately 105 pfu/ml). The same
results were obtained with non-transfected cells (data not
shown). Consistent with the results obtained in HEK-293
cells, IBRS-2 cells transfected with 2B1shRNA displayed a
reduction of approximately 100-fold in virus titer (97%—
1.3  103 pfu/ml). Cells transfected with IRES2shRNA
inhibited virus growth by approximately 50%. Other hair-
pins resulted in little or no inhibition or an increase in virus
titer. Since 2B1shRNA induced the highest level of
inhibition it was used for further analysis.
2B1 shRNA sustains inhibition of viral replication in swine
cells
We examined the duration of the inhibition caused by
2B1shRNA. Forty-eight hours after transfection, IBRS-2
cells were challenged with FMDV A12-IC and samples
were collected at 24, 48, 72 and 96 h post-infection (hpi). As
shown in Fig. 4, 2B1shRNA resulted in a reduction of virus
yield of approximately 100-fold, an effect that persisted for
at least 48 hpi. In the control experiments (vector or GFP),
the virus reached maximum titer at 48 h and then it
decreased as a result of the lysis of the cell monolayer. The
same effect was observed for the 2B1shRNA-transfected
cells but with a delay of approximately 24 h. By 72 h, this
Fig. 5. FMDV shRNAs do not induce the IFN pathway in swine cells.
Quantitative (real time) RT-PCR was used to analyze the levels of PKR,
OAS and Mx1 mRNAs in IBRS-2 cells transfected with shRNAs. 18S
rRNA was used as internal standard control. RNA extracted from IBRS-2
cells treated with 100 U of porcine IFN beta was used as a positive control.
The relative fold induction of each transcript is normalized to that seen in
untransfected cells.
Fig. 4. Duration of inhibition of virus replication by 2B1shRNA. Four sets
of IBRS-2 cells transfected with 2B1shRNA or controls (vector,
GFPshRNA) were infected at 48 h post-transfection with 100 pfu of
FMDVA12-IC. The cultures were incubated for 24, 48, 72 or 96 h and at
the end of the incubation time viral titers were determined. Error bars
represent deviation of the median from two independent experiments.
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controls and then it decreased.
RNAi mediated by plasmids expressing shRNAs does not
induce known pathways of the IFN response in swine cells
FMDV can induce IFN mRNA in several cell types and
in the natural host (Brown et al., 2000; Chinsangaram et al.,
1999, 2001; S. Botton, unpublished data). Furthermore, we
have shown that the IFN activated genes, double-stranded-
RNA-activated protein kinase (PKR) and 2V–5V oligoadeny-
late synthetase (OAS)/RNase L have an important role in
the inhibition of FMDV replication (Chinsangaram et al.,
2001). To rule out the possibility that the inhibition of
FMDV replication by 2B1shRNA was due to activation of
the IFN pathway, we measured the expression of PKR and
OAS as well as Mx1, another IFN activated gene, by
quantitative RT-PCR. As seen in Fig. 5, similar low level
variations in the amounts of PKR, OAS and Mx1 were
observed in cells transfected with vector control as well as
with non-specific and specific shRNAs. Induction of these
genes was confirmed by treatment of the cells with 100 U of
porcine IFNh or FMDV infection (data not shown). Thus,
the inhibitory effect of 2B1shRNA was not mediated by the
activation of the IFN pathway.
2B1shRNA inhibits viral RNA and protein expression in
swine cells
To examine if shRNA specifically affected viral RNA
and protein expression, transfected IBRS-2 cells were
infected with A12-IC at a high multiplicity (MOI = 5) toensure that all cells would be infected. When about 90% of
the cells displayed cytopathic effects (6 hpi) total RNA and
protein were extracted for northern and western blot
analyses. Fig. 6A shows that the level of viral RNA is
markedly reduced (about 70%) in the presence of
2B1shRNA when compared to the levels of RNA in cells
transfected with either vector control or GFPshRNA.
Similar amounts of viral RNA were observed in cells
transfected with either of these later two vectors. FMDV
mRNA is synthesized as a polycistronic message, therefore
cleavage at a specific location results in degradation of the
full length molecule.
Fig. 6. 2B1shRNA inhibits expression of viral RNA and protein. (A) Northern blot analysis of FMDV RNA isolated at 6 hpi from IBRS-2 cells transfected with
shRNAs and infected with FMDV A12-IC (MOI = 5). Viral RNA was detected with a riboprobe to the 3C, 3D coding regions. Lower panel shows rRNA
stained with ethidium bromide as loading control. (B) Western blot analysis of viral proteins isolated from IBRS-2 cells treated under identical conditions. Viral
products were detected with rabbit antiserum against VP1 and VP3 (1:10000) and VP2 and 2B (1:2500). As loading control, tubulin-a was detected with a
mouse monoclonal antibody (1:1000). To detect differences in the synthesis of 2B the blot was overexposed. Therefore, differences in the levels of expression
of the viral structural protein VP3 are less apparent.
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transfected cells, the levels of 2B and other viral protein
products, VP0, VP1 and VP3, were significantly reduced
(more than 80%) as compared to vector or GFPshRNA
transfected cells, without inhibiting the synthesis of host
proteins (tubulin-a). These results indicated that RNAi
specifically targeted FMDV RNA and as a consequence,
there was a decrease in the level of viral proteins.
2B1shRNA inhibits replication of multiple serotypes of
FMDV
One of the concerns in identifying siRNAs to target
FMDV is the antigenic variability of the virus. Alignment of
120 full-length FMDV sequences revealed that 2B is one of
the most conserved sequences across all isolates represent-
ing the 7 FMDV serotypes (Carrillo et al., in press). To test
whether 2B1shRNA, designed on the basis of the sequencefor FMDV A12-IC, was able to inhibit the replication of
other serotypes, we infected 2B1shRNA transfected cells
with FMDV serotypes Asia 1, O1 Campos (O1C), O Taiwan
(O/TAW/2/99), South African Territories type 2 (SAT2) and
C3 Resende (C3R). As seen in Fig. 7A, 2B1shRNA
inhibited the growth of 4 FMDV serotypes; however, the
degree of inhibition varied according to the serotype. As we
previously demonstrated (Fig. 3) greater than 97% inhib-
ition was observed for A12-IC whereas 92% was observed
for O1C which contains an identical target region. Between
74 and 88% inhibition was detected for Asia 1, SAT2, and
O/TAW/2/99 and less than 2% inhibition was observed for
C3R. Statistical analysis indicated that, with the exception
of C3R, the specific inhibition for all the other serotypes
was highly significant (P b 0.01). In addition, differences in
the degree of inhibition between serotypes A12-IC, O1C
and Asia1 were not significant (P N 0.05). Sequence
analyses of the viruses used in our experiments showed
Fig. 7. 2B1shRNA inhibits replication of multiple FMDV serotypes. (A) IBRS-2 cells transfected with 2B1shRNA or control plasmid (GFPshRNA) were
infected at a MOI = 0.0001 with FMDVA12-IC, Asia 1, O1C, SAT2, O/TAW/2/99 or C3R. After 24 h virus titers were determined on BHK-21 cells. Inhibition
is expressed as percentage of titer in 2B1shRNA-transfected cells relative to control shRNA-transfected cells. All inhibition values except for C3R are
statistically significant (P b 0.01). Value differences between A12-IC, O1C and Asia 1 are not significant (P N 0.05). (B) List of the sequences of the target
regions of the viruses used in this experiment.
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targets (Fig. 7B). Nonetheless, 2B1shRNA was effective in
silencing multiple FMDV serotypes.Discussion
In recent years, RNAi has developed into a powerful tool
to down-regulate the expression of endogenous as well as
exogenous or parasitic sequences of the cell (McManus and
Sharp, 2002; Morris et al., 2004). Several recent studies
have demonstrated that RNAi can potentially be used as a
therapeutic or prophylactic mechanism against viruses
(Joost Haasnoot et al., 2003). However, to be effective
against RNA viruses such as FMDV, which are highly
antigenically variable, the siRNAs must be targeted to
conserved regions of the viral genome. Here, we demon-
strated that the replication of different FMDV serotypes in
porcine cells can be inhibited by a shRNA designed against
a region that is highly conserved among multiple viral
genomes.
Initially, we tested the feasibility of silencing FMDV
sequences, using HEK- 293 cells, a cell line known to be
efficient for RNAi (Elbashir et al., 2001). We showed that
several regions across the FMDV A12 viral genome could
be targeted by RNAi. In particular, 2B1shRNA resulted in a
significant reduction of reporter gene activity. Consistent
with these results, when we tested all the shRNAs against
FMDV in porcine cells, 2B1shRNA caused approximately a
100-fold decrease in virus yield indicating that RNAi could
effectively target the FMDV genome in swine cells.
Analyses of viral RNA and protein levels led us to conclude
that in swine cells RNAi induces a potent repression of gene
expression by degrading the cognate mRNA.
We also observed an inhibitory effect for IRES2shRNA,
but it was only approximately 2-fold in both assays. In thisregard, there are differing reports in the literature concerning
a role of the RNA structure in or near the target region of an
siRNA in the efficiency of interference. Studies with
poliovirus, another member of the Picornaviridae family,
have suggested that the IRES region of the 5VUTR might not
be accessible for RNAi (Gitlin et al., 2005; Saleh et al.,
2004). Furthermore, recent studies on HIV-1 have revealed
that this virus can escape from RNAi by evolving an
alternative resistant structure in its RNA genome around an
siRNA-targeted region (Westerhout et al., 2005). In contrast,
for hepatitis C, RNAi targeting of the IRES region has
proven successful (Yokota et al., 2003). Based on these
results, it seems difficult, with our current knowledge, to
predict whether or not a region of highly structured RNA on
a viral target may impose a limitation on the effectiveness of
RNAi.
Neither of the other shRNAs that were effective in the
reporter assay, IRES1 and 3D, resulted in efficient
inhibition of viral growth in swine cells. Differences in
the accessibility of the FMDV RNA when the target is
cloned into a reporter plasmid or present as part of the
complete viral genome may explain this result. Alter-
natively, the degree of inhibition induced by these
shRNAs in the reporter assay may not have been sufficient
to halt virus replication since newly formed viral particles
appear as early as 4 hpi and furthermore, under genetic
pressure, escape resistant mutants arise (Domingo et al.,
2003). Only some sequences of the viral genome may
withstand this level of challenge. This conclusion may
also explain the results of the study examining the
duration of the inhibitory effect of 2B1shRNA after
transfection. Although inhibition extended to 48 h post-
challenge, the virus yield eventually reached the level
found in control transfected cells. Because cell transfection
is not completely efficient, virus replication can occur in
non-transfected cells. In addition, the emergence of viral
T. de los Santos et al. / Virology 335 (2005) 222–231228escape mutants may take over the culture masking any
inhibitory effect.
One of the mechanisms by which mammalian cells can
clear virus infection is through the activation of the IFN
pathway (Sen, 2001). We and others have shown that
FMDV is very sensitive to IFN (Ahl and Rump, 1976;
Chinsangaram et al., 2001). We ruled out the activation of
this pathway after treatment with FMDV-specific shRNAs,
by measuring the expression of the IFN activated genes
PKR, OAS and Mx1. The absence of induction of these
genes suggested that the inhibition of viral growth in swine
cells was due to RNAi, a process that remains active even in
fibroblasts derived from PKR/ mice (Gitlin et al., 2002;
Sledz et al., 2003). Nonetheless, it is possible, that RNAi
may activate a different set of genes involved in viral
clearance.
2B1siRNA targets the highly conserved 2B coding
region of the FMDV genome. Alignment of the full length
sequences of 120 FMDV isolates, revealed that the
sequence of 2B1shRNA is identical in at least 86 of the
common euroasiatic viruses. This conservation probably
indicates the inability of this region to tolerate mutations.
Although persistence of the virus in the field and the
quasispecies nature of the RNA genome have given rise to
new variants, the 2B coding region has remained the most
conserved across all serotypes and subtypes of FMDV
(Carrillo et al., in press). The identification of a sequence
within 2B highly susceptible to RNAi is significant since
one of the limitations in the use of this approach as a
disease control strategy is the incidence of escape mutants
resistant to silencing. We observed that 2B1shRNA
resulted in growth inhibition of FMDV Asia 1, SAT2
and O/TAW/2/99, despite the presence of sequence mis-
matches. Previous reports have indicated that sequence
mismatches can be tolerated causing efficient silencing by
translational repression rather than RNA degradation
(Jackson et al., 2003; Saxena et al., 2003). Other studies,
however, indicate that a single mismatch between a viral
RNA target and an siRNA completely prevents silencing
(Gitlin et al., 2002). More recently, it has been shown that
the location of a mismatch can affect the degree of
silencing (Gitlin et al., 2005; Phipps et al., 2004). For
FMDV C3R, a single base mismatch in the 2B1 target
region was sufficient to abolish silencing. Perhaps the
location of the sequence difference, at nucleotide position
10 from the 5V end of the siRNA, is crucial for RNAi.
Recently, analyses of escape mutants from poliovirus
revealed that this position and the nature of the sequence
change may determine the efficacy of RNAi to cause viral
inhibition (Gitlin et al., 2005).
Our results indicate that for FMDV A12-IC, the
inhibition of viral replication by 2B1shRNA is a result of
reduced levels of viral RNA accumulation. Although
2B1shRNA inhibited viral replication of O1C, Asia 1,
SAT2 and O/TAW/2/99, further studies to determine the
specific mechanism of RNAi involved are required.Our experiments, as well as those of others (Chen et al.,
2004; Kahana et al., 2004), support a proof-of-concept that
siRNA can inhibit FMDV replication, but some significant
issues remain to be addressed. The first is the method of
delivery of the siRNA to an adult organism. Previous
studies in mice report that sequences of HBV can be
targeted by RNAi after hydrodynamic transfection of DNA
expressing shRNAs against HBV (McCaffrey et al., 2003).
In addition, injection of DNA expressing shRNA against
FMDV increased the survival of suckling mice challenged
with the virus (Chen et al., 2004). However, these reports
have limitations. The first introduces the viral genome by
transfection which differs from the events in a natural viral
infection. The second, using a mouse model for FMDV,
requires a very high dose to induce protection (50–100 Ag of
DNA/mouse/~3 g). Considering that the most important
hosts for FMDV are cattle and swine the question arises
about the dose requirement for effectiveness in these
species. Initial reports indicate that retroviral (Barton and
Medzhitov, 2002; Devroe and Silver, 2004) or adenoviral
(Shen et al., 2003; Xia et al., 2002; Zhang et al., 2004)
vectors are able to express shRNAs and induce silencing in
targeted cells. This method of delivery should be more
efficient in targeting and maintaining the RNA silencing
state in tissues or whole organisms. An alternative approach
that seems promising is the cloning of a transgenic animal
that would display specific viral immunity by expression of
shRNAs. This technology has proven successful for silenc-
ing of endogenous genes (Kunath et al., 2003).
The second issue of concern is the selection of viral
escape mutants. As discussed earlier, although we have
identified a conserved region of the viral genome sensitive
to RNAi, resistant mutants may arise. In fact, this might
have been the case when we examined the duration of the
shRNA inhibitory effect. Combination treatment with
multiple siRNAs targeted to conserved regions may prove
useful in avoiding this problem. A large and careful screen
for putative candidates should be performed, challenging
with full length viral genomes. The success of this approach
with poliovirus is encouraging (Gitlin et al., 2005).
Lastly, the potential of negative effects caused by off-
target function of shRNAs may compromise their utility
(Sledz et al., 2003). These problems should be addressed for
each particular set of shRNAs to be used. Nevertheless, the
demonstration that the replication of multiple FMDV
serotypes can be attenuated by a unique conserved siRNA
highlights the potential of using RNAi as a new virus
control strategy.Materials and methods
Cells and viruses
Human embryonic kidney 293 cells (HEK-293, ATCC
CRL1573) were used to assay for luciferase reporter gene
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Disease Diagnostic Laboratory (FADDL) at the Plum Island
Animal Disease Center) were used for expression of
shRNAs and challenge with multiple serotypes of FMDV.
Baby hamster kidney cells clone 21 (BHK-21, clone 13,
ATCC CCL-10) were used for determination of all virus
titers. All cells were cultured in Eagle’s minimal essential
medium (EMEM, Life Technologies, Rockville, MD)
supplemented with either 10% fetal bovine serum (FBS),
amino acids and antibiotics (HEK-293 and IBRS-2) or 10%
bovine calf serum (BCS), 10% tryptose phosphate, amino
acids and antibiotics (BHK-21).
FMDV A12-IC was derived from full length infectious
clone pRMC35 (Rieder et al., 1993). FMDVAsia 1, FMDV
O1C, FMDV SAT2, FMDV O/TAW/2/99 and FMDV C3R
were obtained from FADDL or Dr. Peter Mason, Agricul-
tural Research Service, Plum Island.
Design and cloning of plasmid expressing short hairpin
RNAs
siRNAs were produced in mammalian cells by expression
of short hairpins from a U6 promoter containing plasmid
(pUBX101BbsI). This plasmid is a derivative of pSilencer
1.0-U6 (Ambion, Austin, TX) to which a BbsI site was added
by linker ligation. Two 59-nt long annealed oligonucleotides
with overhang ends were cloned into BbsI/EcoRI sites of
pUBX101BbsI. The oligonucleotides contained a 4 nt
overhang to create a BbsI site (GTTT) plus an added G
followed by a 19-nt sense siRNA sequence, a 9-nt loop
(TTCAAGAGA), a 19-nt reverse complementary antisense
siRNA sequence, an added C and 6 Ts as RNA polymerase
III terminator. The resulting RNA transcripts were expected
to fold back and form a stem–loop structure with a 19 base
pair region homologous to the target sequences of the FMDV
genome. Conserved target sequences were selected from
FMDV A12-IC based on the alignment of sequences of 7
serotypes of FMDV using Clone Manager Suite software
(Scientific and Educational software, Durham, NC) and
Ambion’s web site tool to select potential siRNAs (http://
www.ambion.com/techlib/misc/siRNA_finder). The chosen
sequences were nt 644–662 in the CRE element and nt
966–984 and nt 1017–1035 within the IRES element of the
5VUTR, nt 4033–4051 and nt 4219–4237 within the 2B non-
structural protein coding region, nt 4555–4573 in the 2C
non-structural protein coding region and nt 7810–7828 of the
3D non-structural (polymerase) protein coding region. A
hairpin designed to target the coding region of green
fluorescent protein (nt 106–127) was used as an internal
control to measure off-target silencing caused by expression
of heterologous siRNA (Sui et al., 2002).
Construction of reporter plasmids
Reporter plasmids were constructed by cloning FMDV
A12-IC target sequences of approximately 500–700 bases atthe unique XbaI site of pGL3-Control (Promega, Madison,
WI) downstream of the firefly luciferase (FLuc) gene. The
target for the CRE element was nt 13–716, the target for both
IRES elements was nt 716–1230 (the 5VUTR encompasses nt
1–1116 and includes the CRE element nt 621–678 and the
IRES nt 581–1116), the target for 2B and 2C was nt 3940–
4617 (2B encompasses nt 3979–4440 and 2C nt 4441–5394),
and the target for 3D was nt 7550–8100 (3D encompasses nt
6706–8118). All of the hairpin sequences were contained
within their respective targets. These sequences were
amplified by PCR using pRMC35 as template and the
primer-pairs: for the 5VUTR5VGGATCTAGAGCTAGGGTCQ
TCACCCCTAGC/5VGGATCTAGACCTCTCGCCGTTGTQ
CAGCG for 2B/2C 5VGGATCTAGACTTACTCAAGTTGQ
GCAGG/5VGGATCTAGAGTCGTTGAGGTCCCGTTGC;
and for 3D 5VGGATCTAGACCACCCAAATGCTGAGTGQ
G/5VGGATCTAGAGCGTTCACCCAACGCAGG, that cre-
ated XbaI sites at each end.
Cell transfections and reporter plasmid analyses
HEK-293 cells were co-transfected with plasmids
expressing FMDV shRNAs and derivatives of the reporter
plasmid pGL3-Control (Promega, Madison, WI) containing
FMDV target sequences using Lipofectamine 2000 (Invi-
trogen, Carlsbad, CA). Briefly, 24-well plates were seeded
24 h before transfection with 5  104 cells/well in
OptiMEM-I (Life Technologies, Rockville, MD). Plasmids
expressing FMDV shRNAs and reporter plasmids were co-
transfected at a molar ratio of 30:1 (shRNA/target).
Luciferase activity was assayed 24 h post-transfection using
a Luciferase assay kit (Promega, Madison, WI). Luciferase
values were normalized for specific/control activity and
reported as the average of three independent experiments.
Cell transfection and viral challenge assays
IBRS-2 cells were seeded in 6-well plates with 5  105
cells/well in OptiMEM-I 24 h before transfection. The cells
were transfected with 5 Ag of plasmids expressing shRNAs.
Four hours later 10% FBS was added to the cells without
removing the transfection mixture. After 16 h, the serum-
containing media was replaced by fresh OptiMEM-I and a
second plasmid transfection was performed under identical
conditions. Twenty four hours later, cells were challenged
with FMDVat MOI of 104 and the infection was allowed to
proceed for the indicated times. Viral titers were determined
on BHK-21 cells. For analyses of viral RNA and protein,
transfected cells were challenged with FMDV at MOI of 5
and the samples were collected 6 hpi.
Quantitative RT-PCR
Twenty four hours after transfection or treatment with
porcine IFNh, total RNA was isolated from cell cultures
using an RNeasy mini kit (Qiagen, Valencia, CA). Samples
Table 1
Oligonucleotide primer and probe sequences for amplification of porcine IFN-induced genes used in quantitative (real time) RT-PCR
Gene Accessiona Primer and probe sets Sequence
OAS AJ225090 SBP7 porcine OAS-889Fb 5VCTGTCGTTGGACGATGTATGCT3V
SBP8 porcine OAS-954Rc 5VCAGCCGGGTCCAGAATCA3V
porcine OAS-919Td 5VTCAAGAAACCCAGGCCT3V
Mx1 M65087 SBP9 porcine Mx1-803Fb 5VGAGGTGGACCCCGAAGGA3V
SBP10 porcine Mx1-859Rc 5VCACCAGATCCGGCTTCGT3V
porcine Mx1-824Td 5VAGGACCATCGGGATC3V
PKR AB104654 SBP3 porcine PKR-968Fb 5VGGAAGAAAACAAACACAGCTTGAA3V
SBP4 porcine PKR-1048Rc 5VCCAAATCCACCTGAGCCAATT3V
porcine PKR-994Td 5VCCAGGTT TGTCGAAGAT3V
a NCBI GenBank accession code.
b Forward primer.
c Reverse primer.
d Probe.
T. de los Santos et al. / Virology 335 (2005) 222–231230were treated with DNase I (Sigma, St Louis, MO) and after
heat inactivation of the enzyme, cDNA was synthesized
using M-MLV-RT (Invitrogen, Carlsbad, CA). The relative
levels of PKR, OAS and Mx1 mRNAs were measured using
Ampli Taq gold (Applied Biosystems, Foster City, CA) in a
ABI PRISM 7700 sequence detection system. Primers and
probe were designed using Primer express software
(Applied Biosystems, Foster City, CA). TAqMan probe
labeled with a fluorescent dye was used in this assay. Primer
and probe sequences are listed in Table 1. 18s rRNA was
used as an internal standard control and was amplified for
each sample. Primers and probe used for 18s rRNA were
from the control reagent kit (Applied Biosystems, Foster
City, CA).
Northern and Western blot analyses
Total RNA was extracted from cell cultures using a
RNeasy mini kit (Qiagen, Valencia, CA) and run on a 1%
formaldehyde agarose gel. RNA was transferred to a
cationic charged nylon membrane Zeta-probe (Biorad,
Hercules, CA), UV-crosslinked and hybridized to a digox-
igenin labeled FMDV probe derived from pRMC35
(O’Donnell et al., 2001). The signal was detected by
chemiluminescence using a DIG Luminescent Detection
kit (Roche Applied Science, Indianapolis, IN). For western
analysis protein extracts were prepared from cell cultures in
lysis buffer (10 mM Tris–HCl pH = 8.0, 150 mM NaCl, 15
mM MgCl2, 1% NP-40, 1% sodium deoxycholate, 1 mM
PMSF) for 10 min on ice. After clarification, proteins were
resolved by SDS-PAGE using the Nu-PAGE pre-cast gel
system (Invitrogen, Carlsbad, CA) followed by transfer to
PVDF membranes. Viral proteins were detected with a
mixture of rabbit polyclonal antibodies raised against viral
proteins 2B, VP1, VP2 and VP3 and cellular tubulin-a was
detected with a commercially available monoclonal anti-
body (Lab Vision, Freemont, CA) using the ECL detection
system (Amersham, Piscataway, NJ) according to the
manufacturer’s directions. RNA and proteins were quanti-
tated using AlphaImager 2200 with AlphaEase software(AlphaInnoteck, San Leandro, CA) and normalizing with
respect to the ribosomal RNA bands for the Northern blot or
the tubulin-a band for the Western blot.
Accession numbers for viruses cited in this paper: A12-
A12/UK/119/32- (L11360; M10975); Asia 1/IND/63/72
(AY593795), O1/Campos/BRA/58 (AJ320488), O/TAW/2/
99 (AJ539136), SAT2 (AJ251473), C3Resende (AY593807).Acknowledgments
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